56137-52-1

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 97, p. 3239, 1975 DOI: 10.1021/ja00844a065Organic Syntheses, Coll. Vol. 7, p. 411, 1990

InChI:InChI=1/C11H11NO3/c13-10-9(11(14)15)6-7-12(10)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,14,15)

Upstream product

• 146653-73-8 N,N'-bis(phenyl)cyclopropane-1,1-diamide 
• 5617-70-9 cycl-isopropylidene cyclopropane-1,1-dicarboxylate 
• 62-53-3 aniline 
• 4641-57-0 1-phenylpyrrolidin-2-one 

Downstream Products

• 234443-66-4 3-diazoacetyl-2-oxo-1-phenylpyrrolidine 
• 234443-67-5 4,5-dihydro-3-oxo-6-phenyl-2H-furo[2,3-b]pyrrole 
• 420131-48-2 3-diazoacetyl-3-methyl-2-oxo-1-phenylpyrrolidine 
• 85175-03-7 1-Phenyl-3-(phenylhydroxymethyl)-2-pyrrolidinon 
• 918643-04-6 3-methyl-2-oxo-1-phenylpyrrolidine-3-carboxylic acid 

Relevant academic research and scientific papers

Preparation method and application of compound containing zinc-bound and quinoline skeleton

The invention relates to the field of pharmaceutical chemistry, in particular to a novel zinc-containing binding group-containing quinoline compound. A geometric isomer, a pharmaceutically acceptable salt, solvate or prodrug thereof, a preparation method and thereof, and a pharmaceutical composition containing the compound. The invention also relates to an application of the compound in preparation of drugs for treating and/or preventing diseases mediated by c-Met tyrosine kinase and HDAC. The quinoline compounds, geometric isomers and pharmaceutically acceptable salts, solvates and prodrugs thereof are shown in the specification, and R. 1 , m, Q, X, As described in the claims and the description.

Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy

Owing to the low efficacy and acquired resistance in clinical trials of c-Met inhibitors, based on the synergistic effects between c-Met and HDAC, novel c-Met and HDAC dual inhibitors were designed and synthesized. We introduced 2-pyrrolidinone to form the 5-atoms linker for c-Met inhibitor and hydroxamic acid as a zinc binding motif for HDAC inhibitor. The highly active dual inhibitor 15f showed excellent and balanced activity against both c-Met (IC50 = 12.50 nM) and HDAC1 (IC50 = 26.97 nM). In those tested tumor cell lines, 15f exhibits efficient antiproliferative activity with greater potency than Vorinostat (SAHA) and Cabozantinib (XL184). However, by comparing with an equimolar mixture of SAHA and Foretinib, we did not observe the compounds showed clearly synergistic antiproliferative effect. Nevertheless, compound 15f was found to induce apoptosis and cause cell cycle arrest in G2/M phase. This proof-of-concept study provides an efficient strategy for discovery of multitarget antitumor drugs.

Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors

Co- and post-translational processing are crucial maturation steps to generate functional proteins. MetAP-2 plays an important role in this process, and inhibition of its proteolytic activity has been shown to be important for angiogenesis and tumor growth, suggesting that small-molecule inhibitors of MetAP-2 may be promising options for the treatment of cancer. This work describes the discovery and structure-based hit optimization of a novel MetAP-2 inhibitory scaffold. Of critical importance, a cyclic tartronic diamide coordinates the MetAP-2 metal ion in the active site while additional side chains of the molecule were designed to occupy the lipophilic methionine side chain recognition pocket as well as the shallow cavity at the opening of the active site. The racemic screening hit from HTS campaign 11a was discovered with an enzymatic IC50 of 150 nM. The resynthesized eutomer confirmed this activity and inhibited HUVEC proliferation with an IC50 of 1.9 μM. Its structural analysis revealed a sophisticated interaction pattern of polar and lipophilic contacts that were used to improve cellular potency to an IC50 of 15 nM. In parallel, the molecular properties were optimized on plasma exposure and antitumor efficacy which led to the identification of advanced lead 21.

Copper-catalyzed intermolecular chloro- and bromotrifluoromethylation of alkenes

A highly practical copper-catalyzed intermolecular halotrifluoromethylation of alkenes has been developed under mild reaction conditions. A variety of Cl/Br-containing trifluoromethyl derivatives were directly synthesized from a wide range of alkenes, including electron-deficient and unactivated alkenes.

Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives

Deregulation of c-Met receptor tyrosine kinase activity leads to tumorigenesis and metastasis in animal models. More importantly, the identification of activating mutations in c-Met, as well as MET gene amplification in human cancers, points to c-Met as a

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Synthesis of the tricyclic triamine core of martinelline and martinellic acid

The tricyclic triamine core 27 of martinellic acid (2) has been prepared stereospecifically in eight steps from 2-hydroxymethylaniline in 11% overall yield. The key steps are the addition of 2-hydroxymethylaniline to vinylcyclopropane 14 to prepare cycloaddition precursor 19 in only two steps and an intramolecular [3+2] azomethine ylide cycloaddition reaction to produce tetracycle 20 with >9:1 diastereoselectivity.